Cancer Genetics, which offers personalized genomic tests to improve the diagnosis and treatment of cancer, postponed its IPO on Thursday. The company originally filed for an IPO in December 2011 and attempted to go public in May at a $112 million valuation. After postponing its original IPO effort, the company refiled for a deal that would value the company at $79 million in October. Ultimately, the company further slashed the deal, revising terms to value the company at $65 million, before postponing.
The Rutherford, NJ-based company was founded in 1999 and booked $4 million in sales for the 12 months ended 9/30/2012. Aegis Capital was set to be the sole bookrunner on the deal.
